{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:03:43Z","timestamp":1778511823770,"version":"3.51.4"},"reference-count":0,"publisher":"Ecancer Global Foundation","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ecancer"],"published-print":{"date-parts":[[2009,1,1]]},"DOI":"10.3332\/ecancer.2008.108","type":"journal-article","created":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T15:37:09Z","timestamp":1233329829000},"source":"Crossref","is-referenced-by-count":4,"title":["A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: An update"],"prefix":"10.3332","volume":"3","author":[{"given":"S","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1871","container-title":["ecancermedicalscience"],"original-title":[],"link":[{"URL":"http:\/\/ecancer.org\/journal\/2\/pdf\/108-a-randomised-trial-evaluating-bevacizumab-as-adjuvant-therapy-following-resection-of-ajcc-stage-iib-iic-and-iii-cutaneous-melanoma-an-update.php","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T14:54:00Z","timestamp":1481208840000},"score":1,"resource":{"primary":{"URL":"http:\/\/ecancer.org\/ecms\/2\/108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3332\/ecancer.2008.108","relation":{},"ISSN":["1754-6605"],"issn-type":[{"value":"1754-6605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}